Et studie til at undersøge effektiviteten og sikkerheden af AZD1163 hos deltagere med leddegigt (LaunchPAD-RA)
Et multicentrisk, parallel-gruppe, fase II, randomiseret, dobbeltblindt, 4-armet studie til evaluering af effekt og sikkerhed af AZD1163 hos deltagere med moderat til svært aktiv leddegigt (LaunchPAD-RA)
Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
AZD1163 is a novel bispecific antibody that inhibits the activity of extracellular peptidyl arginine deiminase 2 (PAD2) and peptidyl arginine deiminase 4 (PAD4) enzymes, which are responsible for protein citrullination. In RA, citrullinated proteins lead to the production of pathogenic anti-citrullinated peptide antibodies (ACPA).
This is a Phase II, randomised, double-blind, multicentre, 4 arm placebo-controlled study designed to evaluate the efficacy and safety of AZD1163 in ACPA + adults with moderate-to-severely active RA on standard of care (SoC) (conventional synthetic disease-modifying antirheumatic drugs [csDMARDs] or tumour necrosis factor inhibitor [TNFi] +/- csDMARD).
The study will have a screening period followed by a randomisation period wherein approximately 320 participants will be randomised in a 1:1:1:1 ratio to receive study intervention.
Participants will receive subcutaneous (SC) injection of one of three different doses of AZD1163 or placebo, along with SoC until Week 24 followed by a safety follow-up (FU) period of 28 weeks.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: AstraZeneca Clinical Study Information Center
- Telefonnummer: 1-877-240-9479
- E-mail: information.center@astrazeneca.com
Studiesteder
-
-
-
Caba, Argentina, C1128AAF
- Rekruttering
- Research Site
-
Ciudad de Buenos Aires, Argentina, C1015ABO
- Rekruttering
- Research Site
-
Ciudad de Buenos Aires, Argentina, C1428DUQ
- Rekruttering
- Research Site
-
Córdoba, Argentina, X5000EDC
- Rekruttering
- Research Site
-
San Isidro, Argentina, 1643
- Rekruttering
- Research Site
-
San Miguel de Tucumán, Argentina, T4000AXL
- Rekruttering
- Research Site
-
-
-
-
-
Juiz de Fora, Brasilien, 36010 570
- Rekruttering
- Research Site
-
Pelotas, Brasilien, 96040-010
- Rekruttering
- Research Site
-
Porto Alegre, Brasilien, 90035-903
- Rekruttering
- Research Site
-
Porto Alegre, Brasilien, 90610-001
- Rekruttering
- Research Site
-
Salvador, Brasilien, 41820-020
- Rekruttering
- Research Site
-
São Paulo, Brasilien, 05403-000
- Rekruttering
- Research Site
-
São Paulo, Brasilien, 04266-010
- Trukket tilbage
- Research Site
-
-
-
-
-
Haskovo, Bulgarien, 6304
- Rekruttering
- Research Site
-
Pleven, Bulgarien, 5800
- Rekruttering
- Research Site
-
Sofia, Bulgarien, 1606
- Rekruttering
- Research Site
-
Sofia, Bulgarien, 1113
- Rekruttering
- Research Site
-
Sofia, Bulgarien, 1612
- Rekruttering
- Research Site
-
Sofia, Bulgarien, 1336
- Rekruttering
- Research Site
-
-
-
-
Ontario
-
Niagara Falls, Ontario, Canada, L2E 6A6
- Ikke rekrutterer endnu
- Research Site
-
Ottawa, Ontario, Canada, K1V 1C1
- Ikke rekrutterer endnu
- Research Site
-
Windsor, Ontario, Canada, N8X 5A7
- Rekruttering
- Research Site
-
-
Quebec
-
Trois-Rivières, Quebec, Canada, G9A 3Y2
- Rekruttering
- Research Site
-
-
-
-
-
Providencia, Chile, 7510186
- Trukket tilbage
- Research Site
-
Santiago, Chile, 7500571
- Rekruttering
- Research Site
-
Santiago, Chile, 7500587
- Rekruttering
- Research Site
-
Temuco, Chile, 4810345
- Rekruttering
- Research Site
-
Valdivia, Chile, 5110683
- Rekruttering
- Research Site
-
Victoria, Chile, 4720097
- Rekruttering
- Research Site
-
Viña del Mar, Chile, 2531172
- Rekruttering
- Research Site
-
-
-
-
-
Glasgow, Det Forenede Kongerige, G31 2ER
- Rekruttering
- Research Site
-
Leeds, Det Forenede Kongerige, LS7 4SA
- Rekruttering
- Research Site
-
Luton, Det Forenede Kongerige, LU4 0DZ
- Rekruttering
- Research Site
-
Staffordshire, Det Forenede Kongerige, WS11 5XY
- Trukket tilbage
- Research Site
-
-
-
-
Arizona
-
Glendale, Arizona, Forenede Stater, 85306
- Rekruttering
- Research Site
-
Prescott Valley, Arizona, Forenede Stater, 86314
- Trukket tilbage
- Research Site
-
Tucson, Arizona, Forenede Stater, 85748
- Rekruttering
- Research Site
-
-
California
-
La Jolla, California, Forenede Stater, 92037
- Rekruttering
- Research Site
-
San Dimas, California, Forenede Stater, 91773
- Trukket tilbage
- Research Site
-
San Leandro, California, Forenede Stater, 94578
- Rekruttering
- Research Site
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Rekruttering
- Research Site
-
-
Florida
-
Boynton Beach, Florida, Forenede Stater, 33435
- Trukket tilbage
- Research Site
-
Jacksonville, Florida, Forenede Stater, 32216
- Trukket tilbage
- Research Site
-
South Miami, Florida, Forenede Stater, 33143
- Suspenderet
- Research Site
-
Tampa, Florida, Forenede Stater, 33607
- Trukket tilbage
- Research Site
-
Winter Haven, Florida, Forenede Stater, 33880
- Rekruttering
- Research Site
-
-
Georgia
-
Marietta, Georgia, Forenede Stater, 30060
- Rekruttering
- Research Site
-
-
Illinois
-
Skokie, Illinois, Forenede Stater, 60076
- Rekruttering
- Research Site
-
Willowbrook, Illinois, Forenede Stater, 60527
- Rekruttering
- Research Site
-
-
Louisiana
-
Lake Charles, Louisiana, Forenede Stater, 70605
- Rekruttering
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21224
- Rekruttering
- Research Site
-
Rockville, Maryland, Forenede Stater, 20850
- Rekruttering
- Research Site
-
-
Massachusetts
-
New Bedford, Massachusetts, Forenede Stater, 02740
- Rekruttering
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Forenede Stater, 64151
- Rekruttering
- Research Site
-
St Louis, Missouri, Forenede Stater, 63131
- Rekruttering
- Research Site
-
-
Nevada
-
Henderson, Nevada, Forenede Stater, 89052
- Rekruttering
- Research Site
-
-
South Carolina
-
Myrtle Beach, South Carolina, Forenede Stater, 29572
- Rekruttering
- Research Site
-
-
Texas
-
Austin, Texas, Forenede Stater, 78745
- Rekruttering
- Research Site
-
Baytown, Texas, Forenede Stater, 77521
- Rekruttering
- Research Site
-
Houston, Texas, Forenede Stater, 77089
- Rekruttering
- Research Site
-
Houston, Texas, Forenede Stater, 77027
- Rekruttering
- Research Site
-
Mesquite, Texas, Forenede Stater, 75150
- Rekruttering
- Research Site
-
Tomball, Texas, Forenede Stater, 77375
- Rekruttering
- Research Site
-
-
-
-
-
Aomori, Japan, 030-8553
- Rekruttering
- Research Site
-
Bunkyō City, Japan, 113-8655
- Rekruttering
- Research Site
-
Fukuoka, Japan, 815-8555
- Rekruttering
- Research Site
-
Hamamatsu, Japan, 430-0906
- Rekruttering
- Research Site
-
Hitachi-Naka, Japan, 312-0057
- Rekruttering
- Research Site
-
Iizuka-shi, Japan, 820-8505
- Rekruttering
- Research Site
-
Kawachinagano-shi, Japan, 586-8521
- Rekruttering
- Research Site
-
Matsuyama, Japan, 790-8524
- Rekruttering
- Research Site
-
Meguro-ku, Japan, 152-8902
- Rekruttering
- Research Site
-
Miyazaki, Japan, 880-0834
- Rekruttering
- Research Site
-
Nagoya, Japan, 457-8511
- Rekruttering
- Research Site
-
Okayama, Japan, 700-8557
- Trukket tilbage
- Research Site
-
Sagamihara-shi, Japan, 252-0315
- Rekruttering
- Research Site
-
Sapporo, Japan, 060-0001
- Trukket tilbage
- Research Site
-
Sasebo-shi, Japan, 857-1195
- Rekruttering
- Research Site
-
Sayama-shi, Japan, 350-1305
- Rekruttering
- Research Site
-
Yokohama, Japan, 236-0037
- Rekruttering
- Research Site
-
-
-
-
-
Beijing, Kina, 100730
- Rekruttering
- Research Site
-
Beijing, Kina, 100144
- Rekruttering
- Research Site
-
Changchun, Kina, 130021
- Rekruttering
- Research Site
-
Changsha, Kina, 410008
- Rekruttering
- Research Site
-
Guangzhou, Kina, 510515
- Rekruttering
- Research Site
-
Jiujiang, Kina, 332000
- Rekruttering
- Research Site
-
Kunming, Kina, 650032
- Ikke rekrutterer endnu
- Research Site
-
Linyi, Kina, CN-276003
- Rekruttering
- Research Site
-
Nanchong, Kina, 637000
- Rekruttering
- Research Site
-
Panjin, Kina, 124000
- Rekruttering
- Research Site
-
Pingxiang, Kina, 337055
- Rekruttering
- Research Site
-
Shantou, Kina, 515041
- Rekruttering
- Research Site
-
Xuzhou, Kina, 221009
- Rekruttering
- Research Site
-
Yangzhou, Kina, 225001
- Rekruttering
- Research Site
-
Zhengzhou, Kina, 450000
- Rekruttering
- Research Site
-
-
-
-
-
Chihuahua City, Mexico, 31000
- Rekruttering
- Research Site
-
Estado de México, Mexico, 50090
- Rekruttering
- Research Site
-
Guadalajara, Mexico, 44160
- Ikke rekrutterer endnu
- Research Site
-
Guadalajara, Mexico, 44650
- Ikke rekrutterer endnu
- Research Site
-
Guadalajara, Mexico, 44690
- Ikke rekrutterer endnu
- Research Site
-
Gustavo A. Madero, Mexico, 07300
- Ikke rekrutterer endnu
- Research Site
-
Mexicali, Mexico, 021100
- Ikke rekrutterer endnu
- Research Site
-
Mexico City, Mexico, 06700
- Rekruttering
- Research Site
-
Monterrey, Mexico, 64460
- Ikke rekrutterer endnu
- Research Site
-
Mérida, Mexico, 97070
- Rekruttering
- Research Site
-
San Luis Potosí City, Mexico, 78213
- Trukket tilbage
- Research Site
-
-
-
-
-
Krakow, Polen, 30-727
- Rekruttering
- Research Site
-
Krakow, Polen, 30-002
- Rekruttering
- Research Site
-
Torun, Polen, 87-100
- Rekruttering
- Research Site
-
Warsaw, Polen, 00-874
- Rekruttering
- Research Site
-
Wroclaw, Polen, 50-244
- Rekruttering
- Research Site
-
-
-
-
-
Caguas, Puerto Rico, 00725
- Rekruttering
- Research Site
-
-
-
-
-
Barcelona, Spanien, 08041
- Rekruttering
- Research Site
-
Barcelona, Spanien, 08035
- Rekruttering
- Research Site
-
Barcelona, Spanien, 08003
- Rekruttering
- Research Site
-
Málaga, Spanien, 29009
- Rekruttering
- Research Site
-
Sabadell, Spanien, 08208
- Rekruttering
- Research Site
-
Santiago de Compostela, Spanien, 15706
- Rekruttering
- Research Site
-
Valencia, Spanien, 46026
- Rekruttering
- Research Site
-
-
-
-
-
Brackenfell, Sydafrika, 7560
- Trukket tilbage
- Research Site
-
Cape Town, Sydafrika, 7500
- Rekruttering
- Research Site
-
Durban, Sydafrika, 4319
- Rekruttering
- Research Site
-
Pinelands, Sydafrika, 7405
- Rekruttering
- Research Site
-
Pretoria, Sydafrika, 0002
- Rekruttering
- Research Site
-
Pretoria, Sydafrika, 0083
- Trukket tilbage
- Research Site
-
Somerset West, Sydafrika, 7130
- Rekruttering
- Research Site
-
-
-
-
-
Bad Doberan, Tyskland, 18209
- Trukket tilbage
- Research Site
-
Berlin, Tyskland, 10777
- Rekruttering
- Research Site
-
Hamburg, Tyskland, 20095
- Rekruttering
- Research Site
-
Sendenhorst, Tyskland, 48324
- Rekruttering
- Research Site
-
-
-
-
-
Ivano-Frankivsk, Ukraine, 76018
- Rekruttering
- Research Site
-
Kyiv, Ukraine, 04050
- Rekruttering
- Research Site
-
Kyiv, Ukraine, 03037
- Rekruttering
- Research Site
-
Kyiv, Ukraine, 04210
- Rekruttering
- Research Site
-
Kyiv, Ukraine, 02002
- Rekruttering
- Research Site
-
Kyiv, Ukraine, 03049
- Rekruttering
- Research Site
-
Uzhhorod, Ukraine, 88000
- Rekruttering
- Research Site
-
Vinnytsia, Ukraine, 21029
- Rekruttering
- Research Site
-
Vinnytsia, Ukraine, 21018
- Rekruttering
- Research Site
-
-
-
-
-
Budapest, Ungarn, 1027
- Rekruttering
- Research Site
-
Budapest, Ungarn, 1023
- Rekruttering
- Research Site
-
Budapest, Ungarn, 1036
- Trukket tilbage
- Research Site
-
Debrecen, Ungarn, 4032
- Rekruttering
- Research Site
-
Gyula, Ungarn, 5700
- Rekruttering
- Research Site
-
Szeged, Ungarn, 6725
- Rekruttering
- Research Site
-
Székesfehérvár, Ungarn, 8000
- Rekruttering
- Research Site
-
Veszprém, Ungarn, 8200
- Rekruttering
- Research Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
-
Inclusion
- Diagnosed with adult-onset RA as defined by the 2010 ACR/EULAR classification criteria for at least 12 weeks prior to screening.
- Moderately-to-severely active RA as defined by: a. >= 6 swollen joints on 66SJC and >= 6 tender joints on 68TJC; b. CRP > upper limit of normal.
- Have a positive ACPA at screening.
- A history of inadequate response, or loss of response, or intolerance to: a. at least one csDMARD treatment, AND/OR b. At least one and at most 2 TNFi.
- A history of at least 12 weeks treatment and >= 4 weeks stable on a csDMARD and/or SC TNFi prior to the day of randomisation.
-
Exclusion
- History or evidence of an alternate autoimmune or other condition that could confound the diagnosis of RA. Participants with RA and secondary Sjogren's disease are eligible.
- Have received or planning to receive any biologic DMARDs (except for TNFi) or targeted synthetic DMARDs.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: AZD1163 Dose 1
Participants will receive subcutaneous (SC) injection of AZD1163 Dose 1 in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24. |
Participants will receive SC injection of one of three different doses of AZD1163 in combination with SoC (csDMARD or TNFi +/- csDMARDSoC) until Week 24. |
|
Eksperimentel: AZD1163 Dose 2
Participants will receive SC injection of AZD1163 Dose 2 in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24. |
Participants will receive SC injection of one of three different doses of AZD1163 in combination with SoC (csDMARD or TNFi +/- csDMARDSoC) until Week 24. |
|
Eksperimentel: AZD1163 Dose 3
Participants will receive SC injection of AZD1163 Dose 3 in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24. |
Participants will receive SC injection of one of three different doses of AZD1163 in combination with SoC (csDMARD or TNFi +/- csDMARDSoC) until Week 24. |
|
Placebo komparator: Placebo
Participants will receive SC injection of placebo matched with AZD1163 dose in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24. |
Participants will receive SC injection of placebo matched to AZD1163 in combination with SoC (csDMARD or TNFi +/- csDMARDSoC) until Week 24. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in Disease Activity Score-C-Reactive Protein (DAS28-CRP) at Week 12
Tidsramme: Week 12
|
Change from baseline in DAS28-CRP at Week 12. |
Week 12
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants Achieving American College of Rheumatology Response Criteria 20 (ACR20) at Week 12
Tidsramme: Week 12
|
Proportion of participants achieving a 20% improvement in ACR response criteria at Week 12. |
Week 12
|
|
Percentage of Participants Achieving ACR50 at Week 12
Tidsramme: Week 12
|
Proportion of participants achieving a 50% improvement in ACR response criteria at Week 12. |
Week 12
|
|
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 12
Tidsramme: Week 12
|
Change from baseline in CDAI at Week 12. |
Week 12
|
|
Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 12
Tidsramme: Week 12
|
Change from baseline in SDAI at Week 12. |
Week 12
|
|
Summary statistics to evaluate the PK of AZD1163
Tidsramme: Week 0 to Week 24 and Follow-Up
|
AZD1163 concentrations in serum |
Week 0 to Week 24 and Follow-Up
|
|
Summary statistics to evaluate the immunogenicity of AZD1163
Tidsramme: Week 0 to Week 24 and Follow-Up
|
ADA (incidence, prevalence, and titres) |
Week 0 to Week 24 and Follow-Up
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- D9640C00003
- 2025-522076-85 (Anden identifikator: EU CT number)
- 167070 (Registry Identifier: IND)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD-delingstidsramme
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-delingsadgangskriterier
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .